TARA

Insider Trades

Name	Value	Action	Price	Last Price
Zummo JacquelineChief R&D Officer $6.1k1.1k shares SellApr 8, 2026 $5.40 $4.76
Zummo JacquelineChief R&D Officer $119k22.6k shares SellApr 1, 2026 $5.26 $4.76
Levy Richard SDirector $64k20k shares BuyMay 14, 2025 $3.19 $4.76
Zummo JacquelineChf Scientific Operations Off $96k21.2k shares SellMar 26, 2025 $4.53 $4.76

News

businesswire.comTradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Tradingbusinesswire.comJun 15

globenewswire.comProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHAglobenewswire.comMay 20

seekingalpha.comProtara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcriptseekingalpha.comMay 19

globenewswire.comProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026globenewswire.comMay 18

benzinga.comProtara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Studybenzinga.comMay 15

Trade TARA

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

CEO: Jesse Shefferman
IPO Date: Oct 22, 2014

Market Data

Last available Jun 20, 2026

Open: $4.13
High: $4.20
Low: $3.98
Volume: 803.7K
Avg Volume: 700.7K
52W High: $7.82
52W Low: $2.77

Valuation

Market: Last available Jun 20, 2026 / Fundamentals: Last available Dec 31, 2025

Market Cap: $154M
Enterprise Value: $142M
Dividend Yield: 0.00%

Financials

Last available Dec 31, 2025

Free Cash Flow: $-56M
Revenue: $0
Net Income: $-57M
Cash: $50M
Debt: $3.4M

Events

EarningsAug 10

EPS est. -0.33